HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

NCT02775227 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Fistula
Pancreatic Neoplasms

Interventions

DRUG: Hydrocortisone
DRUG: Pasireotide

Sponsor

Helsinki University Central Hospital